165 related articles for article (PubMed ID: 27990485)
21. Class II Eplet Mismatch Modulates Tacrolimus Trough Levels Required to Prevent Donor-Specific Antibody Development.
Wiebe C; Rush DN; Nevins TE; Birk PE; Blydt-Hansen T; Gibson IW; Goldberg A; Ho J; Karpinski M; Pochinco D; Sharma A; Storsley L; Matas AJ; Nickerson PW
J Am Soc Nephrol; 2017 Nov; 28(11):3353-3362. PubMed ID: 28729289
[TBL] [Abstract][Full Text] [Related]
22. Correlation and agreement between eplet mismatches calculated using serological, low-intermediate and high resolution molecular human leukocyte antigen typing methods.
Fidler S; D'Orsogna L; Irish AB; Lewis JR; Wong G; Lim WH
Oncotarget; 2018 Mar; 9(17):13116-13124. PubMed ID: 29568344
[TBL] [Abstract][Full Text] [Related]
23. hlaR: A rapid and reproducible tool to identify eplet mismatches between transplant donors and recipients.
Johnson AC; Zhang J; Cliff Sullivan H; Wiebe C; Bray R; Gebel H; Larsen CP
Hum Immunol; 2022 Mar; 83(3):248-255. PubMed ID: 35101308
[TBL] [Abstract][Full Text] [Related]
24. Combining Sensitive Crossmatch Assays With Donor/Recipient Human Leukocyte Antigen Eplet Matching Predicts Living-Donor Kidney Transplant Outcome.
Meneghini M; Melilli E; Martorell J; Revuelta I; Rigol-Monzó E; Manonelles A; Montero N; Cucchiari D; Diekmann F; Cruzado JM; Gil-Vernet S; Grinyó JM; Bestard O
Kidney Int Rep; 2018 Jul; 3(4):926-938. PubMed ID: 29989033
[TBL] [Abstract][Full Text] [Related]
25. Urinary CXCL10 specifically relates to HLA-DQ eplet mismatch load in kidney transplant recipients.
San Segundo D; Guiral-Foz SA; Benito-Hernández A; Fernández AR; Arnau A; Valero R; Ramos-Barrón MA; García-Unzueta MT; Gómez-Ortega JM; López-Hoyos M; Ruiz JC; Rodrigo E
Transpl Immunol; 2022 Feb; 70():101494. PubMed ID: 34774739
[TBL] [Abstract][Full Text] [Related]
26. Epitope analysis of HLA-DQ antigens: what does the antibody see?
Tambur AR; Rosati J; Roitberg S; Glotz D; Friedewald JJ; Leventhal JR
Transplantation; 2014 Jul; 98(2):157-66. PubMed ID: 25003284
[TBL] [Abstract][Full Text] [Related]
27. HLA class II Eplet mismatch predicts De Novo DSA formation post lung transplant.
Walton DC; Cantwell L; Hiho S; Ta J; Wright S; Sullivan LC; Snell GI; Westall GP
Transpl Immunol; 2018 Dec; 51():73-75. PubMed ID: 30321645
[TBL] [Abstract][Full Text] [Related]
28. Graft and patient outcomes of zero-human leucocyte-antigen-mismatched deceased and live donor kidney transplant recipients.
Lim WH; Gray NA; Chadban SJ; Pilmore H; Wong G
Transpl Int; 2015 May; 28(5):610-8. PubMed ID: 25689280
[TBL] [Abstract][Full Text] [Related]
29. Association of mismatches for HLA-DR with incidence of posttransplant hip fracture in kidney transplant recipients.
Opelz G; Döhler B
Transplantation; 2011 Jan; 91(1):65-9. PubMed ID: 21452411
[TBL] [Abstract][Full Text] [Related]
30. Clinical relevance of HLA-DQ eplet mismatch and maintenance immunosuppression with risk of allosensitization after kidney transplant failure.
Tran J; Alrajhi I; Chang D; Sherwood KR; Keown P; Gill J; Kadatz M; Gill J; Lan JH
Front Genet; 2024; 15():1383220. PubMed ID: 38638120
[TBL] [Abstract][Full Text] [Related]
31. HLA-DPB1 molecular mismatches are risk factors for acute rejection and low 5-year graft function in first kidney transplants.
de Marco R; Requião-Moura LR; Raimundo TRF; Mourão TB; Rampim GF; Medina-Pestana JO; Tedesco-Silva H; Gerbase-DeLima M
HLA; 2023 Mar; 101(3):228-238. PubMed ID: 36461794
[TBL] [Abstract][Full Text] [Related]
32. Belatacept with time-limited tacrolimus coimmunosuppression modifies the 3-year risk of eplet mismatch in kidney transplantation.
Johnson AC; Zhang J; Karadkhele G; Gragert L; Hertzberg V; Larsen CP
Am J Transplant; 2024 Feb; 24(2):260-270. PubMed ID: 37778459
[TBL] [Abstract][Full Text] [Related]
33. Sensitization trends after renal allograft failure: the role of DQ eplet mismatches in becoming highly sensitized.
Singh P; Filippone EJ; Colombe BW; Shah AP; Zhan T; Harach M; Gorn C; Frank AM
Clin Transplant; 2016 Jan; 30(1):71-80. PubMed ID: 26529289
[TBL] [Abstract][Full Text] [Related]
34. Contribution of non-HLA incompatibility between donor and recipient to kidney allograft survival: genome-wide analysis in a prospective cohort.
Reindl-Schwaighofer R; Heinzel A; Kainz A; van Setten J; Jelencsics K; Hu K; Loza BL; Kammer M; Heinze G; Hruba P; Koňaříková A; Viklicky O; Boehmig GA; Eskandary F; Fischer G; Claas F; Tan JC; Albert TJ; Patel J; Keating B; Oberbauer R;
Lancet; 2019 Mar; 393(10174):910-917. PubMed ID: 30773281
[TBL] [Abstract][Full Text] [Related]
35. The antibody response to an HLA mismatch: a model for nonself-self discrimination in relation to HLA epitope immunogenicity.
Duquesnoy RJ
Int J Immunogenet; 2012 Feb; 39(1):1-9. PubMed ID: 21981757
[TBL] [Abstract][Full Text] [Related]
36. Application of an epitope-based allocation system in pediatric kidney transplantation.
Kausman JY; Walker AM; Cantwell LS; Quinlan C; Sypek MP; Ierino FL
Pediatr Transplant; 2016 Nov; 20(7):931-938. PubMed ID: 27662811
[TBL] [Abstract][Full Text] [Related]
37. The effects of HLA mismatching and immunosuppressive therapy on early rejection outcome in pediatric heart transplant recipients.
Herzberg GZ; Rossi AF; Courtney M; Gelb BD
J Heart Lung Transplant; 1998 Dec; 17(12):1195-200. PubMed ID: 9883760
[TBL] [Abstract][Full Text] [Related]
38. Human leukocyte antigen mismatches associated with increased risk of rejection, graft failure, and death independent of initial immunosuppression in renal transplant recipients.
Lim WH; Chadban SJ; Clayton P; Budgeon CA; Murray K; Campbell SB; Cohney S; Russ GR; McDonald SP
Clin Transplant; 2012; 26(4):E428-37. PubMed ID: 22672477
[TBL] [Abstract][Full Text] [Related]
39. Case report: binding of a clinically relevant human leukocyte antigen-DQα-specific antibody in a kidney graft recipient is inhibited by donor-type human leukocyte antigen-DQβ chain.
Mikkelsen S; Korsholm T; Iburg A; Petersen MS; Møller BK
Transplant Proc; 2013 Apr; 45(3):1209-12. PubMed ID: 23622661
[TBL] [Abstract][Full Text] [Related]
40. Donor-Derived Cell-Free DNA at 1 Month after Kidney Transplantation Relates to HLA Class II Eplet Mismatch Load.
González-López E; Ocejo-Vinyals JG; Renuncio-García M; Roa-Bautista A; San Segundo Arribas D; Escagedo C; García-Saiz MDM; Valero R; García-Berbel P; Ruíz San Millán JC; Rodrigo E
Biomedicines; 2023 Oct; 11(10):. PubMed ID: 37893114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
